Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Feb. 28, 2017	Mar. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 28, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		36,780,397

Consolidated Condensed Statements of Income (Loss) (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016
Income Statement [Abstract]
Net sales	$ 85,602	$ 87,434	$ 262,729	$ 260,471
Cost of sales (exclusive of intangible amortization)	41,810	43,900	128,895	127,682
Gross profit	43,792	43,534	133,834	132,789
Operating expenses
Research and development	5,951	5,808	18,573	18,116
Sales and marketing	19,469	20,955	58,481	63,534
General and administrative	7,000	6,901	22,952	22,897
Amortization of intangibles	4,360	4,458	12,886	13,356
Change in fair value of contingent consideration	122	(31)	(15,386)	630
Acquisition, restructuring and other items, net	1,750	3,042	12,028	9,098
Medical device excise tax	0	435	0	2,416
Total operating expenses	38,652	41,568	109,534	130,047
Operating income	5,140	1,966	24,300	2,742
Other (expenses) income
Interest expense	(635)	(809)	(2,171)	(2,607)
Interest income	8	2	15	4
Other income (expense)	44	(214)	(269)	(570)
Total other expenses, net	(583)	(1,021)	(2,425)	(3,173)
Income (loss) before income tax expense (benefit)	4,557	945	21,875	(431)
Income tax expense	1,670	351	3,954	84
Net income (loss)	$ 2,887	$ 594	$ 17,921	$ (515)
Income (loss) per share
Basic (in usd per share)	$ 0.08	$ 0.02	$ 0.49	$ (0.01)
Diluted (in usd per share)	$ 0.08	$ 0.02	$ 0.48	$ (0.01)
Basic weighted average shares outstanding (in shares)	36,625	36,146	36,557	36,083
Diluted weighted average shares outstanding (in shares)	37,126	36,390	37,068	36,083

Consolidated Condensed Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 2,887	$ 594	$ 17,921	$ (515)
Other comprehensive income (loss), before tax:
Unrealized gain on interest rate swap	0	58	0	219
Unrealized gain (loss) on marketable securities	(2)	27	0	2
Foreign currency translation (loss)	(41)	79	(906)	(360)
Other comprehensive (loss) income, before tax	(43)	164	(906)	(139)
Income tax expense related to items of other comprehensive income	0	(30)	0	(83)
Other comprehensive (loss) income, net of tax	(43)	134	(906)	(222)
Total comprehensive income (loss), net of tax	$ 2,844	$ 728	$ 17,015	$ (737)

Consolidated Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 35,571	$ 32,333
Marketable securities	1,203	1,653
Accounts receivable, net of allowances of $3,089 and $4,372, respectively	46,302	52,867
Inventories	57,681	55,370
Prepaid income taxes	309	788
Prepaid expenses and other	3,985	3,243
Total current assets	145,051	146,254
Property, plant and equipment, net	46,180	48,284
Other assets	1,757	3,827
Intangible assets, net	150,078	166,577
Goodwill	361,252	361,252
Total assets	704,318	726,194
CURRENT LIABILITIES
Accounts payable	15,357	15,616
Accrued liabilities	20,753	21,942
Current portion of long-term debt	5,000	16,250
Current portion of contingent consideration	9,531	12,919
Total current liabilities	50,641	66,727
Long-term debt, net of current portion	92,519	104,291
Deferred income taxes	25,304	21,684
Contingent consideration, net of current portion	3,104	25,356
Other long-term liabilities	1,000	908
Total liabilities	172,568	218,966
Commitments and contingencies (Footnote N)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $.01 per share, 75,000,000 shares authorized; 36,780,397 and 36,420,403 shares issued and 36,780,397 and 36,278,098 shares outstanding at February 28, 2017 and May 31, 2016, respectively	370	363
Additional paid-in capital	531,171	525,775
Retained earnings (deficit)	1,906	(16,015)
Treasury stock, 0 and 142,305 shares at February 28, 2017 and May 31, 2016, respectively, at cost	0	(2,104)
Accumulated other comprehensive loss	(1,697)	(791)
Total stockholders’ equity	531,750	507,228
Total liabilities and stockholders' equity	$ 704,318	$ 726,194

Consolidated Condensed Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 3,089	$ 4,372
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	36,780,397	36,420,403
Common stock, shares outstanding	36,780,397	36,278,098
Treasury stock, shares	0	142,305

Consolidated Condensed Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016
Cash flows from operating activities:
Net income (loss)	$ 17,921	$ (515)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	18,455	21,289
Stock based compensation	5,078	4,500
Change in fair value of contingent consideration	(15,386)	630
Gain on contingent consideration for IPR&D Write-off	3,624	(388)
Bad debt expense	(605)	1,355
Impairment loss on indefinite-lived intangible assets	3,822	675
Write-off of other assets	2,685	0
Write-off of other assets	(535)	0
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	6,898	2,492
Intercompany	(2,585)	1,457
Prepaid expenses and other	(1,215)	(782)
Accounts payable, accrued and other liabilities	(1,405)	(4,041)
Net cash provided by operating activities	36,752	26,672
Cash flows from investing activities:
Additions to property, plant and equipment	(2,258)	(1,895)
Payments for Repurchase of Warrants	0	2,000
Payments to Acquire Businesses, Net of Cash Acquired	0	18
Proceeds from sale or maturity of marketable securities	450	25
Net cash used in investing activities	(1,808)	(3,888)
Cash flows from financing activities:
Proceeds from issuance of and borrowings on long-term debt	116,471	0
Repayment of long-term debt	(139,131)	(11,250)
Deferred financing costs on long-term debt	(1,335)	0
Payment of contingent consideration previously established in purchase accounting	(9,850)	(9,850)
Repurchase of common stock	(7,840)	0
Proceeds from exercise of stock options and employee stock purchase plan	10,269	1,933
Net cash used in financing activities	(31,416)	(19,167)
Effect of exchange rate changes on cash and cash equivalents	(290)	(111)
Increase in cash and cash equivalents	3,238	3,506
Cash and cash equivalents at beginning of period	32,333	18,391
Cash and cash equivalents at end of period	35,571	21,897
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of fixed assets	$ 99	$ 37

Consolidated Condensed Statement of Stockholders' Equity (unaudited) - 9 months ended Feb. 28, 2017 - USD ($) $ in Thousands	Total	Common Stock [Member]	Common Stock [Member] Performance Shares [Member]	Common Stock [Member] Restricted Stock Units (RSUs) [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Beginning Balance at May. 31, 2016	$ 507,228	$ 363			$ 525,775	$ (16,015)	$ (791)	$ (2,104)
Beginning Balance, Shares at May. 31, 2016		36,420,403
Beginning Balance,Treasury Shares at May. 31, 2016	(142,305)							(142,305)
Net income (loss)	$ 17,921					17,921
Exercise of stock options	9,307	$ 7			9,300
Exercise of stock options, Shares		704,794
Issuance/Cancellation of performance share units and restricted stock units, net	(457)	$ 1			(458)
Issuance/Cancellation of performance share units and restricted stock units, net, Shares			23,405	144,915
Purchase of common stock under ESPP	1,419	$ 1			1,418
Purchase of common stock under ESPP, Shares		129,185
Stock based compensation	$ 5,078				5,078
Treasury stock retirement, Shares	642,305	(642,305)						642,305
Treasury stock retirement		$ (2)			(9,942)			$ 9,944
Common stock repurchased	$ (7,840)							$ (7,840)
Common stock repurchased, shares								(500,000)
Other comprehensive income, net of tax	(906)						(906)
Ending Balance at Feb. 28, 2017	$ 531,750	$ 370			$ 531,171	$ 1,906	$ (1,697)	$ 0
Ending Balance, Shares at Feb. 28, 2017		36,780,397
Ending Balance,Treasury Shares at Feb. 28, 2017	0							0

Consolidated Condensed Financial Statements	9 Months Ended
Consolidated Condensed Financial Statements	Feb. 28, 2017
Accounting Policies [Abstract]
Consolidated Condensed Financial Statements	CONSOLIDATED CONDENSED FINANCIAL STATEMENTS The consolidated condensed balance sheet as of February 28, 2017, the consolidated condensed statement of stockholders’ equity and consolidated condensed statement of cash flows for the nine months ended February 28, 2017 and the consolidated condensed statements of income (loss) and consolidated condensed statements of comprehensive income (loss) for the three and nine months ended February 28, 2017 and February 29, 2016 have been prepared by us and are unaudited. The consolidated condensed balance sheet as of May 31, 2016 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 28, 2017 (and for all periods presented) have been made. The unaudited interim consolidated condensed financial statements for the three and nine months ended February 28, 2017 and February 29, 2016 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated. Recent Developments During the third quarter of fiscal year 2017, the Company announced to employees an Operational Consolidation strategy which included the consolidation of the Manchester, GA and Denmead, UK facilities into the Glens Falls and Queensbury, NY manufacturing facilities. As part of the plan, the Company expects to incur restructuring expenses including: severance and retention, equipment transfer, set-up and purchases, regulatory expenses, lease termination expenses and other miscellaneous expenses. The plan is expected to be completed in the third quarter of fiscal year 2018. During the third quarter of fiscal year 2017, the Board of Directors approved a resolution and the Company retired all 642,305 treasury shares. During the second quarter of fiscal year 2017, the Company made the decision to discontinue their investment in the TiLo product that was acquired in August 2013 as part of the Clinical Devices acquisition. This decision resulted in the write-off of the acquired in-process research and development (IPR&D) of $3.6 million along with a $3.1 million gain from the reduction in the fair value of contingent consideration liability associated with future milestones that will no longer be met. During the second quarter of fiscal year 2017, the Company revised the sales projections for the AngioVac product as a result of reviews performed by executive management across all products. The adjustments to the sales projections resulted in a $13.4 million gain from the reduction in the fair value of the contingent liability that is based on projected sales volume over the contractual earn out period. During the second quarter of fiscal year 2017, the Company decided to terminate its agreements with EmboMedics. The termination of these agreements resulted in a write-off of the initial $2.0 million investment in EmboMedics (See note C). During the second quarter of fiscal year 2017, the Board of Directors approved a share repurchase program (the “Repurchase Program”) under which they authorized the Company the option to repurchase up to $25.0 million of its outstanding common stock during the twenty-four month period ending November 6, 2018. During the second quarter of fiscal year 2017, the Company repurchased 500,000 shares of common stock in the open market at an aggregate cost of $7.8 million under the Repurchase Program. During the second quarter of fiscal year 2017, the Company entered into a new credit facility ("The Facility") which provides for a $100.0 million senior secured term loan facility and a $150.0 million senior secured revolving credit facility along with up to a $20.0 million sublimit for letters of credit and a $5.0 million limit for swing line loans. With the proceeds from the new credit facility, the existing credit facility that was entered into in September 2013 was paid down in full.

Inventories

9 Months Ended

Feb. 28, 2017

Inventory Disclosure [Abstract]

Inventories

INVENTORIES

Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of February 28, 2017 and May 31, 2016, inventories consisted of the following:



	Feb 28, 2017		May 31, 2016
	(in thousands)
Raw materials	$	19,057	$	21,669
Work in process	11,947		10,700
Finished goods	26,677		23,001
Inventories	$	57,681	$	55,370

Other Assets	9 Months Ended
Other Assets	Feb. 28, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	OTHER ASSETS On March 2, 2015, the Company filed an 8-K stating that it executed a non-binding letter of intent to enter into a strategic relationship with privately-held EmboMedics Inc., which develops injectable and resorbable embolic microspheres. On April 9, 2015, the Company entered into a License, Distribution, Manufacturing and Purchase Option Agreement with EmboMedics Inc, subject to certain approvals by EmboMedics shareholders. Under the terms of the agreement, AngioDynamics received an exclusive worldwide license to market and sell, upon regulatory clearances, EmboMedics’ microsphere technology. AngioDynamics has the ability to determine the manufacturing of the products. On December 7, 2015, AngioDynamics made an initial $2.0 million purchase of non-transferable warrants in a subsidiary of EmboMedics which become exercisable upon a change of control of EmboMedics. The Company does not have significant influence, or control of the subsidiary. This initial investment was recorded at cost and the Company reviewed for impairment at each balance sheet date. The warrants are not exercisable at the original issue date or the balance sheet date as they only become exercisable upon a change of control, termination of the agreement or delivery of an offer notice. In the second quarter of fiscal year 2017, the Company decided to terminate its agreements with EmboMedics. The termination of these agreements resulted in a write-off of the initial $2.0 million investment in EmboMedics and is included in "Acquisition, restructuring and other items, net" on the Consolidated Condensed Statements of Income (Loss).

Goodwill and Intangible Assets

9 Months Ended

Feb. 28, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from one to eighteen years and the weighted average useful life at February 28, 2017 is 12.9 years. We periodically review the estimated useful lives of our intangible assets and review such assets or asset groups for impairment, based on estimated future cash flows, whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs based on respective fair market values at the date of acquisition.

The Company's annual testing for impairment of goodwill was completed as of December 31, 2016. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company performed its step one assessment as prescribed by FASB ASC Topic 350, Intangibles - Goodwill and Other as of December 31, 2016 and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.

Even though we determined that there was no goodwill impairment as of December 31, 2016, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2017. We continued to assess for potential impairment through February 28, 2017 and noted no events that would be considered a triggering event. There were no adjustments to goodwill for the nine months ended February 28, 2017.

As of February 28, 2017 and May 31, 2016, intangible assets consisted of the following:



	February 28, 2017
	Gross carrying value		Accumulated amortization			Net carrying value
	(in thousands)
Product technologies	$	148,374	$	(58,345	)	$	90,029
Customer relationships	88,322		(50,131		)	38,191
Trademarks	28,400		(8,357		)	20,043
Licenses	5,037		(4,289		)	748
Distributor relationships	2,150		(1,083		)	1,067
	$	272,283	$	(122,205	)	$	150,078



	May 31, 2016
	Gross carrying value		Accumulated amortization			Net carrying value
	(in thousands)
Product technologies	$	148,387	$	(51,313	)	$	97,074
Customer relationships	88,389		(47,133		)	41,256
Trademarks	28,470		(6,242		)	22,228
In-process R&D acquired	3,600		—			3,600
Licenses	7,931		(6,716		)	1,215
Distributor relationships	2,150		(946		)	1,204
	$	278,927	$	(112,350	)	$	166,577

Amortization expense for the three months ended February 28, 2017 and February 29, 2016 was $4.4 million and $4.5 million, respectively. Amortization expense for the nine months ended February 28, 2017 and February 29, 2016 was $12.9 million and $13.4 million, respectively.

Expected future amortization expense related to the intangible assets is as follows:



(in thousands)
Remainder of 2017	$	4,398
2018	16,849
2019	16,138
2020	14,556
2021	13,604
2022 and thereafter	84,533
	$	150,078

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Liabilities

9 Months Ended

Feb. 28, 2017

Payables and Accruals [Abstract]

Accrued Liabilities

ACCRUED LIABILITIES

As of February 28, 2017 and May 31, 2016, accrued liabilities consisted of the following:



	Feb 28, 2017		May 31, 2016
	(in thousands)
Payroll and related expenses	$	9,807	$	9,414
Royalties	2,473		2,489
Accrued severance	1,606		1,524
Sales and franchise taxes	832		565
Outside services	1,085		2,063
Other	4,950		5,887
	$	20,753	$	21,942

Long Term Debt

9 Months Ended

Feb. 28, 2017

Debt Disclosure [Abstract]

Long Term Debt

LONG TERM DEBT

On November 7, 2016, the Company entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and JPMorgan Chase Bank, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.

The Credit Agreement provides for a $100.0 million senior secured term loan facility (“Term Loan”) and a $150.0 million senior secured revolving credit facility, which includes up to a $20.0 million sublimit for letters of credit and a $5.0 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Loan, the “Facilities”).

On November 7, 2016, the Company borrowed $100.0 million under the Term Loan and approximately $16.5 million under the Revolving Facility to repay the balance of $116.5 million under the former credit agreement. As of February 28, 2017 the revolver was paid off in full. As of February 28, 2017 and May 31, 2016 the carrying value of long-term debt approximates its fair market value.

The proceeds of the Revolving Facility may be used for general corporate purposes of the Company and its subsidiaries. The Facilities have a five year maturity. Interest on both the Term Loan and Revolving Facility are based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. In case of default, the interest rate may be increased by 2.0%. The Revolving Facility carries a commitment fee of 0.20% to 0.35% per annum on the unused portion. The interest rate at February 28, 2017 was 2.29%.

Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.

The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows:

•maximum leverage ratio of consolidated total indebtedness* to consolidated adjusted EBITDA* of not greater than 3.50 to 1.00 (during certain periods following material acquisitions shall be increased to 3.75 to 1.00).

• fixed charge coverage ratio of consolidated adjusted EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.

* The definitions of consolidated total indebtedness and adjusted EBITDA are maintained in our credit agreement included as an exhibit to our Form 8-k filed on November 10, 2016.

The Company was in compliance with both covenants as of February 28, 2017.

The Company's maturities of principal obligations under the credit agreement are as follows, as of February 28, 2017:



(in thousands)
Remainder of 2017	$	1,250
2018	5,000
2019	5,000
2020	7,500
2021	11,250
2022	68,750
Total term loan	98,750
Revolving facility	—
Total debt	98,750
Less: Unamortized debt issuance costs	(1,231		)
Total	97,519
Less: Current portion of long-term debt	(5,000		)
Total long-term debt, net	$	92,519

Income Taxes	9 Months Ended
Income Taxes	Feb. 28, 2017
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur. The estimated annual effective tax rate prior to discrete items was 42.9% in the third quarter of fiscal 2017, as compared to 46.0% for the same period in fiscal 2016. The Company’s effective tax rate differs from the U.S. statutory rate primarily due to impact of the deferred tax liability related to indefinite lived intangibles, foreign taxes and state taxes. A valuation allowance is established if it is more likely than not that all, or a portion of the deferred tax asset will not be realized. The Company has established that it is more likely than not that some, or all of their deferred tax assets will not be recognized in future years. Consequently, the Company continues to maintain a full U.S. valuation allowance on its net deferred tax assets. Management will continue to reevaluate the positive and negative evidence at each reporting period and if future results as projected in the U.S. and our tax planning strategies are favorable, the valuation allowance may be removed, which could have a favorable material impact on our results of operations in the period in which it is recorded.

Share-Based Compensation	9 Months Ended
Share-Based Compensation	Feb. 28, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION We have two stock-based compensation plans that provide for the issuance of up to approximately 9.5 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to our employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to our employees, directors and other service providers. We also have an employee stock purchase plan. For the three months ended February 28, 2017 and February 29, 2016, share-based payment expense was $1.7 million for both periods. For the nine months ended February 28, 2017 and February 29, 2016, share-based payment expense was $5.1 million and $4.5 million, respectively. In the nine months ended February 28, 2017 and February 29, 2016, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. In the first quarter of fiscal year 2017, the Company granted performance share awards under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the three year requisite service period. The performance criteria are based on the total shareholder return ("TSR") of the Company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of the Company's shares on the date of grant and use a Monte Carlo simulation model. As of February 28, 2017, there were $14.4 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Equity	9 Months Ended
Equity	Feb. 28, 2017
Equity [Abstract]
Equity	EQUITY On November 6, 2016 the, Board of Directors approved a share repurchase program (the "Repurchase Program") under which they authorized the Company the option to repurchase up to $25.0 million of its outstanding common stock during the twenty-four month period ending November 6, 2018. During the second quarter of fiscal year 2017, the Company repurchased 500,000 shares of common stock in the open market at an aggregate cost of $7.8 million under the Repurchase Program. As of February 28, 2017, $17.2 million remained available for repurchase under the Repurchase Program. In February 2017, the Company retired 642,305 shares of treasury stock. These retired shares are now included in the Company’s pool of authorized but unissued shares. The retired stock had a carrying value of approximately $9.9 million and $0.01 was the par value that was deducted from Common Stock and the remaining $9.9 million is deducted from Additional Paid-in Capital.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Earnings Per Share

9 Months Ended

Feb. 28, 2017

Earnings Per Share [Abstract]

Earnings Per Share

EARNINGS PER SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.

The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 28, 2017 and February 29, 2016 (in thousands):



	Three Months Ended		Nine Months Ended
	Feb 28, 2017	Feb 29, 2016	Feb 28, 2017	Feb 29, 2016
Basic	36,625	36,146	36,557	36,083
Effect of dilutive securities	501	244	511	—
Diluted	37,126	36,390	37,068	36,083

Securities excluded as their inclusion would be anti-dilutive	1,040	3,394	973	3,038

Segment and Geographic Information

9 Months Ended

Feb. 28, 2017

Segment Reporting [Abstract]

Segment and Geographic Information

SEGMENT AND GEOGRAPHIC INFORMATION

We consider our business to be a single operating segment entity engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease, oncology and surgery on a global basis. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.

The table below summarizes net sales by product category (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 28, 2017		Feb 29, 2016		Feb 28, 2017		Feb 29, 2016
Net sales
Peripheral Vascular	$	48,496	$	49,779	$	152,800	$	147,940
Vascular Access	23,680		24,911		72,238		74,576
Oncology/Surgery	12,993		12,054		35,837		35,859
Supply Agreement	433		690		1,854		2,096
Total	$	85,602	$	87,434	$	262,729	$	260,471

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 28, 2017		Feb 29, 2016		Feb 28, 2017		Feb 29, 2016
Net sales
United States	$	67,366	$	69,501	$	209,901	$	208,523
International	17,803		17,243		50,974		49,852
Supply Agreement	433		690		1,854		2,096
Total	$	85,602	$	87,434	$	262,729	$	260,471

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Fair Value

9 Months Ended

Feb. 28, 2017

Fair Value Disclosures [Abstract]

Fair Value

FAIR VALUE

On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. Our recurring fair value measurements using significant unobservable inputs (Level 3) relate to our marketable securities, which are comprised of auction rate securities, and our contingent consideration liabilities.

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2017 and May 31, 2016 (in thousands of dollars):



	Fair Value Measurements using inputs considered as:						Fair Value at February 28, 2017
	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,203	$	1,203
Total	—		—		1,203		1,203
Total Financial Assets	$	—	$	—	$	1,203	$	1,203
Financial Liabilities:
Contingent consideration for acquisition earn out	—		—		12,635		12,635
Total Financial Liabilities	$	—	$	—	$	12,635	$	12,635


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2016
	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,653	$	1,653
Total	—		—		1,653		1,653
Total Financial Assets	$	—	$	—	$	1,653	$	1,653
Financial Liabilities:
Contingent consideration for acquisition earn out	—		—		38,275		38,275
Total Financial Liabilities	$	—	$	—	$	38,275	$	38,275

There were no transfers between Level 1, 2 and 3 for the three and nine months ended February 28, 2017.

The table below presents the changes in fair value components of Level 3 instruments in the three and nine months ended February 28, 2017 (in thousands of dollars):



	Three Months Ended February 28, 2017
	Financial Assets		Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, November 30, 2016	1,203		12,513
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration	—		122
Balance, February 28, 2017	$	1,203	$	12,635



	Nine Months Ended February 28, 2017
	Financial Assets			Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)			Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2016	1,653			38,275
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration	—			(15,386		)
Currency gain (loss) from remeasurement	—			(154		)
Proceeds from sale or maturity of marketable securities	(450		)	—
Contingent consideration payments	—			(10,100		)
Balance, February 28, 2017	$	1,203		$	12,635

During the second quarter of fiscal year 2017, the Company made the decision to discontinue their investment in the TiLo product that was acquired in August 2013 as part of the Clinical Devices acquisition. This decision resulted in the write-off of the acquired in-process research and development (IPR&D) of $3.6 million along with a $3.1 million gain from the reduction in the fair value of contingent consideration liability associated with future milestones that will no longer be met. In addition, the Company revised the sales projections for the AngioVac product as a result of reviews performed by executive management across all products. The adjustments to the sales projections resulted in a $13.4 million gain from the reduction in the fair value of the contingent liability that is based on projected sales volume over the contractual earn out period.

Contingent Consideration for Acquisition Earn Outs

Some of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statements of income.

We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements and is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. At February 28, 2017, the revenue based payments are being calculated based on our current sales projections which is at the minimums for contingent payments.

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2017 (in thousands of dollars):



	Fair value at		Valuation
	Feb 28, 2017		Technique	Unobservable Input	Range
Revenue based payments	$	12,635	Discounted cash flow	Discount rate	4%
				Probability of achieving sales	100%
				Projected fiscal year of payment	2017 - 2019

At February 28, 2017, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $13.0 million. The milestones, including sales projections, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2017 to 2019 in order for the associated consideration to be paid.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

9 Months Ended

Feb. 28, 2017

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

MARKETABLE SECURITIES

Marketable securities, which can be government agency bonds, auction rate investments or corporate commercial paper, are classified as “available-for-sale securities” and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold an investment in an auction rate security that is high credit quality and generally achieved with municipal bond insurance. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the security in the near term. We have not participated in any recent auctions. As of February 28, 2017 and May 31, 2016, we had $1.2 million and $1.7 million, respectively, in investments in one auction rate security. The authorities are current in their interest payments on the security. The auction rate security will mature in 2029.

As of February 28, 2017 and May 31, 2016, marketable securities consisted of the following (in thousands of dollars):



As of February 28, 2017	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,350	$	—	$	(147	)	$	1,203
	$	1,350	$	—	$	(147	)	$	1,203



As of May 31, 2016	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,800	$	—	$	(147	)	$	1,653
	$	1,800	$	—	$	(147	)	$	1,653

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Feb. 28, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation. AngioDynamics v. biolitec On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we sought judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court granted key portions of our motion for summary judgment in our legal case against biolitec. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million. Biolitec appealed this judgment. On August 23, 2013, the U.S. Court of Appeals for the Second Circuit dismissed biolitec’s appeal. In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortiously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction. On January 14, 2014, the District Court entered judgment in our favor as to liability. On March 18, 2014, the District Court entered judgment in our favor against Biolitec AG, Biomed Technology Holdings, Ltd., and Wolfgang Neuberger, jointly and severally, in the amount of $74.9 million. On March 11, 2015, the U.S. Court of Appeals for the First Circuit affirmed the judgment. The defendants petitioned to the U.S. Supreme Court for a writ of certiorari. The Supreme Court denied the petition on November 30, 2015. The defendants also filed an appeal with the U.S. Court of Appeals for the First Circuit regarding civil contempt sanctions imposed by the Massachusetts District Court as a result of defendants’ completion of the downstream merger in violation of the Court’s injunction. On May 6, 2016, the First Circuit issued an opinion rejecting this latest appeal. On October 11, 2016, defendants petitioned the U.S. Supreme Court for a writ of certiorari from that decision. We opposed the petition, and the Supreme Court denied the petition on January 9, 2017. On February 18, 2016, the Massachusetts District Court issued an order compelling the Massachusetts defendants to provide post-judgment discovery intended to aid us in potentially collecting our judgment. On March 21, 2016, the Massachusetts defendants noticed an appeal from this order. On August 31, 2016, the First Circuit dismissed that appeal. On June 27, 2016, we filed a motion asking the Massachusetts District Court to impose sanctions on the Massachusetts defendants for their failure to comply with the post-judgment discovery order. On December 26, 2016, we filed a further motion seeking to compel defendants to provide additional post-judgment discovery; the Massachusetts District Court granted our motion on February 17, 2017. On March 8, 2017, the Massachusetts defendants filed another notice of appeal to the First Circuit Court of Appeals, challenging the District Court’s denial of their motion to vacate the civil contempt sanctions in effect against them On November 13, 2014, the U.S. District Court for the District of Massachusetts issued summonses to four Biolitec entities - Biolitec U.S., Inc., Biolitec Holding U.S., Inc., Biolitec Medical Devices, Inc., and CeramOptec Industries, Inc. - pursuant to Massachusetts trustee process. We sought to use this process to attach the assets of these entities in order to satisfy our judgment. The trustee process was automatically stayed when the four Biolitec entities filed Chapter 7 petitions in the U.S. Bankruptcy Court for the District of Delaware. However, on November 3, 2015, the Delaware Bankruptcy Court granted our request to modify the automatic stay to allow us to seek a default against the four Biolitec entities pursuant to trustee process. On January 21, 2016, the four Chapter 7 cases were transferred at our request to the U.S. Bankruptcy Court for the District of New Jersey. On February 17, 2017, we filed our motion for default against the four Chapter 7 Debtors in the trustee process in the Massachusetts District Court. On August 29, 2013, we became co-plaintiffs in an adversary proceeding in the United States Bankruptcy Court for the District of New Jersey entitled Cyganowski, Trustee, et al. v. Biolitec U.S., Inc., et al. In this action, we assert claims of conversion, unjust enrichment, tortious interference, and unfair competition against various biolitec entities for alleged violation of Bankruptcy Court settlement and sale orders under which we acquired certain assets of Biolitec, Inc. On September 3, 2013, we, along with our co-plaintiff, obtained a temporary restraining order against the defendants in this action. On January 22, 2015, the Bankruptcy Court entered a permanent injunction on our behalf for an additional two years. Our damages claims in this adversary proceeding have been stayed since the Chapter 7 bankruptcy filings of the four Biolitec Debtors in April 2015. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but had asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. Meanwhile, we filed petitions for reexamination in the US Patent and Trademark Office ("PTO") which seek to invalidate all three patents asserted by Bard in the litigation. Our petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the PTO Board of Appeals and Interferences for all three reexams. The parties completed briefing on the appeals and oral argument was held on June 18, 2015. The Patent Office has issued decisions in the three appeals. In one (issued on March 11, 2016 for US Patent No. 7,785,302), the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. In the second (issued on March 24, 2016 for U.S. Patent No. 7,959,615), the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third (issued on March 29 for U.S. Patent No. 7,947.022) the rejections of all twenty claims under reexamination were affirmed. Bard has since filed Requests for Rehearing in all three reexamination appeals and the Company filed Requests for Rehearing in two of the reexamination appeals (the ‘302 and ‘615 patent reexaminations). Each party has filed comments in Opposition to the other party’s Rehearing Requests,. The PTO has since issued decisions denying all Rehearing Requests - - on February 1, 2017 for the ‘302; on February 17, 2017 for the ‘022; and on February 21, 2017 for the ‘615. In the ‘302 and ‘022, the PTO modified its characterization of one prior art reference. The Utah Action has been stayed pending final resolution of the PTO process. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 10, 2015, C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (“Bard”) filed suit in the United States District Court for the District of Delaware claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the “Delaware Action). Bard is seeking unspecified damages and other relief. The patents asserted in the Delaware Action are different than those asserted in the Utah Action. On June 1, 2015, we filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court. On January 12, 2016, the court issued a decision denying both motions. We have since served an Answer and Counterclaim to which Bard has served a Reply. On March 10, 2016, the Court held a case management conference, and, on March 14, 2016, the court entered a Scheduling Order which set, inter alia, a Markman hearing for March 10, 2017, a summary judgment hearing for December 8, 2017 and trial for March 12, 2018. The parties have since served various discovery requests on each other, and have been producing documents to each other; on May 27, 2016 Bard served its Infringement Contentions which identified all the port products accused of infringement; and, on June 24, 2016, we served Invalidity Contentions which detail various grounds for invalidating the three asserted patents. The parties completed briefing on the claim construction issues and the Markman hearing was held on March 10, 2017. A decision is expected on or about May 12, 2017. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. Governmental Investigations LC Beads In June 2014 we received a subpoena from the U.S. Department of Justice (the “DOJ”) requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding BTG International, Inc.’s LC Bead® product beginning in 2003. RITA Medical Systems and AngioDynamics, Inc., after its acquisition of RITA, was the exclusive distributor of LC Beads in the United States from 2006 through December 31, 2011. We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome. We are unable at this time to reasonably estimate the amount or range of any loss, although it is possible that the amount of such loss could be material. In accordance with ASC 450, "Contingencies," or "ASC 450," no amount in respect of any potential liability in this matter, including for penalties, fines or other sanctions, has been accrued in the consolidated financial statements. EVLT In April 2015 we received a subpoena from the DOJ requesting documents in relation to a criminal and civil investigation the DOJ is conducting regarding purported promotion of certain of AngioDynamics’ VenaCure EVLT products for un-cleared indications. We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome. We are unable at this time to reasonably estimate the amount or range of any loss, although it is possible that the amount of such loss could be material. In accordance with ASC 450, Contingencies, no amount in respect of any potential liability in this matter, including for penalties, fines or other sanctions, has been accrued in the consolidated financial statements.

Acquisition, Restructuring and Other Items, Net

9 Months Ended

Feb. 28, 2017

Restructuring and Related Activities [Abstract]

Acquisition, Restructuring and Other Items, Net

ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET

Acquisition, Restructuring and Other Items

For the three months and nine months ended February 28, 2017 and February 29, 2016 acquisition, restructuring and other items, net consisted of:



	Three Months Ended				Nine Months Ended
	Feb 28, 2017		Feb 29, 2016		Feb 28, 2017		Feb 29, 2016
	(in thousands)				(in thousands)
Legal	$	1,528	$	1,468	$	5,162	$	5,402
Intangible and other asset impairment	—		—		5,604		384
Plant consolidation	217		—		217		—
Other	5		1,574		1,045		3,312
Total	$	1,750	$	3,042	$	12,028	$	9,098

Restructuring

The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations.

Operational Consolidation

On February 1, 2017, the Company announced to employees an operational consolidation plan (the “plan”) to consolidate our manufacturing facilities in Manchester, GA and Denmead, UK into the Glens Falls and Queensbury, NY facilities. This plan will streamline and optimize the manufacturing functions into one centralized location increasing the utilization of the Glens Falls and Queensbury facilities, optimizing inventory and reducing cost of goods sold through savings in overhead expenses and direct labor. The restructuring activities associated with the plan are expected to be completed in the third quarter of fiscal year 2018.

The following table provides a summary of our estimated costs associated with the plan:



Type of cost		Total estimated amount expected to be incurred (in millions)
Termination benefits		$1.75 to $2.25
Equipment transfer		$2.25 to $2.50
Regulatory filings		$0.75 to $1.00
Contract cancellations		$0.75 to $1.00
Other		$0.75 to $1.00
		$6.25 to $7.75

The Company recorded restructuring charges related to the plan in the third quarter of fiscal year 2017 of $0.2 million for the three months ended and $0.2 million for the nine months ended. There were no costs associated with this plan in the prior year. Termination benefits are only earned if an employee stays until their termination date; therefore, the expenses related to termination benefits are being recorded ratably over the service period.

The following table presents the costs incurred in the third quarter of fiscal year 2017:



Three and nine months ended February 28, 2017:

			Equipment				Contract
	Termination		Transfer		Regulatory		Cancellation		Other
(in thousands)	Benefits		Costs		Filings		Costs		Costs

Acquisition, restructuring, one-time and other	$	202	$	—	$	—	$	—	$	15

	$	202	$	—	$	—	$	—	$	15

The Company made no cash payments in the third quarter of fiscal year 2017 associated with our restructuring initiatives associated with the plan.

The Company’s restructuring liability of $0.2 million is mainly comprised of accruals for termination benefits which are included in accrued expenses on the consolidated condensed balance sheet.

Recently Issued Accounting Pronouncements	9 Months Ended
Recently Issued Accounting Pronouncements	Feb. 28, 2017
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In April 2015, the Financial Accounting Standards Board ("FASB") issued ASC Update No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. Update No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Update No. 2015-03 is effective for annual reporting periods beginning after December 15, 2015 and interim periods within those reporting periods. Early adoption is permitted for financial statements that have not been previously issued. This update was applied retrospectively as of August 31, 2016. The deferred financing fees included in other assets of $0.9 million was classified as long-term debt at May 31, 2016 in the consolidated condensed balance sheet. This update did not impact the results of our operations. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 provides a single, comprehensive accounting model for revenues arising from contracts with customers that supersedes most of the existing revenue recognition guidance, including industry-specific guidance. Under this model, revenue is recognized at an amount that an entity expects to be entitled to upon transferring control of goods or services to a customer, as opposed to when risks and rewards transfer to a customer under existing revenue recognition guidance. ASU 2014-09 is effective for the Company beginning in its fiscal year 2019, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluating the impact of ASU 2014-09 on its consolidated financial statements. In July 2015, the FASB issued ASC Update No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Update No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Update No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Update No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of Update No. 2015-11 is not expected to have a material impact on our financial position or results of operations. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10). Update No. 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. Update No. 2016-01 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years and early application is permitted. The Company is currently in the process of evaluating the impact. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term or twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-02 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Based Compensation (Topic 718: Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies and improves various aspects of ASC 718 for share-based payments, including income tax items and the classification of these items on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-09 on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805), which clarifies the definition of a business by providing a more robust framework to evaluate whether transactions should be accounted for as an acquisition of assets or business. This update is expected to reduce the number of transactions that will be accounted for as an acquisition of a business. ASU 2017-01 is effective for annual periods beginning after December 15, 2017. The effects of this update will depend on future acquisitions. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by eliminating steps from the goodwill impairment test. ASU 2017-04 should be adopted for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company will evaluate the impact of ASU 2017-04 during its next goodwill impairment test.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

Recently Issued Accounting Pronouncements (Policies)	9 Months Ended
Recently Issued Accounting Pronouncements (Policies)	Feb. 28, 2017
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In April 2015, the Financial Accounting Standards Board ("FASB") issued ASC Update No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. Update No. 2015-03 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Update No. 2015-03 is effective for annual reporting periods beginning after December 15, 2015 and interim periods within those reporting periods. Early adoption is permitted for financial statements that have not been previously issued. This update was applied retrospectively as of August 31, 2016. The deferred financing fees included in other assets of $0.9 million was classified as long-term debt at May 31, 2016 in the consolidated condensed balance sheet. This update did not impact the results of our operations. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 provides a single, comprehensive accounting model for revenues arising from contracts with customers that supersedes most of the existing revenue recognition guidance, including industry-specific guidance. Under this model, revenue is recognized at an amount that an entity expects to be entitled to upon transferring control of goods or services to a customer, as opposed to when risks and rewards transfer to a customer under existing revenue recognition guidance. ASU 2014-09 is effective for the Company beginning in its fiscal year 2019, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company is currently in the process of evaluating the impact of ASU 2014-09 on its consolidated financial statements. In July 2015, the FASB issued ASC Update No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. Update No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Update No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Update No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of Update No. 2015-11 is not expected to have a material impact on our financial position or results of operations. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10). Update No. 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. Update No. 2016-01 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years and early application is permitted. The Company is currently in the process of evaluating the impact. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term or twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-02 on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Based Compensation (Topic 718: Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies and improves various aspects of ASC 718 for share-based payments, including income tax items and the classification of these items on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 and early application is permitted. The Company is currently in the process of evaluating the impact of ASU 2016-09 on its consolidated financial statements.

Inventories (Tables)

9 Months Ended

Feb. 28, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of February 28, 2017 and May 31, 2016, inventories consisted of the following:



	Feb 28, 2017		May 31, 2016
	(in thousands)
Raw materials	$	19,057	$	21,669
Work in process	11,947		10,700
Finished goods	26,677		23,001
Inventories	$	57,681	$	55,370

Goodwill and Intangible Assets (Tables)

9 Months Ended

Feb. 28, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

As of February 28, 2017 and May 31, 2016, intangible assets consisted of the following:



	February 28, 2017
	Gross carrying value		Accumulated amortization			Net carrying value
	(in thousands)
Product technologies	$	148,374	$	(58,345	)	$	90,029
Customer relationships	88,322		(50,131		)	38,191
Trademarks	28,400		(8,357		)	20,043
Licenses	5,037		(4,289		)	748
Distributor relationships	2,150		(1,083		)	1,067
	$	272,283	$	(122,205	)	$	150,078



	May 31, 2016
	Gross carrying value		Accumulated amortization			Net carrying value
	(in thousands)
Product technologies	$	148,387	$	(51,313	)	$	97,074
Customer relationships	88,389		(47,133		)	41,256
Trademarks	28,470		(6,242		)	22,228
In-process R&D acquired	3,600		—			3,600
Licenses	7,931		(6,716		)	1,215
Distributor relationships	2,150		(946		)	1,204
	$	278,927	$	(112,350	)	$	166,577

Schedule of Future Amortization Expense

Expected future amortization expense related to the intangible assets is as follows:



(in thousands)
Remainder of 2017	$	4,398
2018	16,849
2019	16,138
2020	14,556
2021	13,604
2022 and thereafter	84,533
	$	150,078

Long Term Debt (Tables)

9 Months Ended

Feb. 28, 2017

Debt Disclosure [Abstract]

Schedule of Debt

The Company's maturities of principal obligations under the credit agreement are as follows, as of February 28, 2017:



(in thousands)
Remainder of 2017	$	1,250
2018	5,000
2019	5,000
2020	7,500
2021	11,250
2022	68,750
Total term loan	98,750
Revolving facility	—
Total debt	98,750
Less: Unamortized debt issuance costs	(1,231		)
Total	97,519
Less: Current portion of long-term debt	(5,000		)
Total long-term debt, net	$	92,519

Earnings Per Share (Tables)

9 Months Ended

Feb. 28, 2017

Earnings Per Share [Abstract]

Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding

The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 28, 2017 and February 29, 2016 (in thousands):



	Three Months Ended		Nine Months Ended
	Feb 28, 2017	Feb 29, 2016	Feb 28, 2017	Feb 29, 2016
Basic	36,625	36,146	36,557	36,083
Effect of dilutive securities	501	244	511	—
Diluted	37,126	36,390	37,068	36,083

Securities excluded as their inclusion would be anti-dilutive	1,040	3,394	973	3,038

Segment and Geographic Information (Tables)

9 Months Ended

Feb. 28, 2017

Segment Reporting [Abstract]

Summary of Net Sales by Product Category

The table below summarizes net sales by product category (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 28, 2017		Feb 29, 2016		Feb 28, 2017		Feb 29, 2016
Net sales
Peripheral Vascular	$	48,496	$	49,779	$	152,800	$	147,940
Vascular Access	23,680		24,911		72,238		74,576
Oncology/Surgery	12,993		12,054		35,837		35,859
Supply Agreement	433		690		1,854		2,096
Total	$	85,602	$	87,434	$	262,729	$	260,471

Summary of Net Sales by Geographic Area

The table below presents net sales by geographic area based on external customer location (in thousands of dollars):



	Three Months Ended				Nine Months Ended
	Feb 28, 2017		Feb 29, 2016		Feb 28, 2017		Feb 29, 2016
Net sales
United States	$	67,366	$	69,501	$	209,901	$	208,523
International	17,803		17,243		50,974		49,852
Supply Agreement	433		690		1,854		2,096
Total	$	85,602	$	87,434	$	262,729	$	260,471

Fair Value (Tables)

9 Months Ended

Feb. 28, 2017

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2017 and May 31, 2016 (in thousands of dollars):



	Fair Value Measurements using inputs considered as:						Fair Value at February 28, 2017
	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,203	$	1,203
Total	—		—		1,203		1,203
Total Financial Assets	$	—	$	—	$	1,203	$	1,203
Financial Liabilities:
Contingent consideration for acquisition earn out	—		—		12,635		12,635
Total Financial Liabilities	$	—	$	—	$	12,635	$	12,635


	Fair Value Measurements using inputs considered as:						Fair Value at May 31, 2016
	Level 1		Level 2		Level 3
Financial Assets:
Marketable securities
U.S. government agency obligations	$	—	$	—	$	1,653	$	1,653
Total	—		—		1,653		1,653
Total Financial Assets	$	—	$	—	$	1,653	$	1,653
Financial Liabilities:
Contingent consideration for acquisition earn out	—		—		38,275		38,275
Total Financial Liabilities	$	—	$	—	$	38,275	$	38,275

Fair Value Measurements Using Significant Unobservable Inputs

The table below presents the changes in fair value components of Level 3 instruments in the three and nine months ended February 28, 2017 (in thousands of dollars):



	Three Months Ended February 28, 2017
	Financial Assets		Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, November 30, 2016	1,203		12,513
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration	—		122
Balance, February 28, 2017	$	1,203	$	12,635



	Nine Months Ended February 28, 2017
	Financial Assets			Financial Liabilities
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)			Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance, May 31, 2016	1,653			38,275
Total gains or losses (realized/unrealized):
Change in present value of contingent consideration	—			(15,386		)
Currency gain (loss) from remeasurement	—			(154		)
Proceeds from sale or maturity of marketable securities	(450		)	—
Contingent consideration payments	—			(10,100		)
Balance, February 28, 2017	$	1,203		$	12,635

Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2017 (in thousands of dollars):



	Fair value at		Valuation
	Feb 28, 2017		Technique	Unobservable Input	Range
Revenue based payments	$	12,635	Discounted cash flow	Discount rate	4%
				Probability of achieving sales	100%
				Projected fiscal year of payment	2017 - 2019

Marketable Securities (Tables)

9 Months Ended

Feb. 28, 2017

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

As of February 28, 2017 and May 31, 2016, marketable securities consisted of the following (in thousands of dollars):



As of February 28, 2017	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,350	$	—	$	(147	)	$	1,203
	$	1,350	$	—	$	(147	)	$	1,203



As of May 31, 2016	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Available-for-sale securities:
Government agency obligations	$	1,800	$	—	$	(147	)	$	1,653
	$	1,800	$	—	$	(147	)	$	1,653

Acquisition, Restructuring and Other Items, Net (Tables)

9 Months Ended

Feb. 28, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

The following table presents the costs incurred in the third quarter of fiscal year 2017:



Three and nine months ended February 28, 2017:

			Equipment				Contract
	Termination		Transfer		Regulatory		Cancellation		Other
(in thousands)	Benefits		Costs		Filings		Costs		Costs

Acquisition, restructuring, one-time and other	$	202	$	—	$	—	$	—	$	15

	$	202	$	—	$	—	$	—	$	15

The following table provides a summary of our estimated costs associated with the plan:



Type of cost		Total estimated amount expected to be incurred (in millions)
Termination benefits		$1.75 to $2.25
Equipment transfer		$2.25 to $2.50
Regulatory filings		$0.75 to $1.00
Contract cancellations		$0.75 to $1.00
Other		$0.75 to $1.00
		$6.25 to $7.75

For the three months and nine months ended February 28, 2017 and February 29, 2016 acquisition, restructuring and other items, net consisted of:



	Three Months Ended				Nine Months Ended
	Feb 28, 2017		Feb 29, 2016		Feb 28, 2017		Feb 29, 2016
	(in thousands)				(in thousands)
Legal	$	1,528	$	1,468	$	5,162	$	5,402
Intangible and other asset impairment	—		—		5,604		384
Plant consolidation	217		—		217		—
Other	5		1,574		1,045		3,312
Total	$	1,750	$	3,042	$	12,028	$	9,098

Consolidated Condensed Financial Statements Narrative (Details) - USD ($)		3 Months Ended	9 Months Ended
	Nov. 06, 2016	Feb. 28, 2017	Feb. 28, 2017	Nov. 07, 2016
Equity, Class of Treasury Stock [Line Items]
Treasury stock retirement			642,305
Value of shares repurchased			$ 7,840,000
JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member] \| Term Loan \| Credit Facility
Equity, Class of Treasury Stock [Line Items]
Line of credit		$ 100,000,000	100,000,000	$ 100,000,000
JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member] \| Revolving Credit Facility \| Credit Facility
Equity, Class of Treasury Stock [Line Items]
Line of credit		150,000,000	150,000,000	150,000,000
JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member] \| Letter of Credit [Member] \| Credit Facility
Equity, Class of Treasury Stock [Line Items]
Line of credit		20,000,000	20,000,000	20,000,000
JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member] \| Bridge Loan [Member] \| Credit Facility
Equity, Class of Treasury Stock [Line Items]
Line of credit		5,000,000	5,000,000	$ 5,000,000
Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock authorized for repurchase	$ 25,000,000.0	$ 25,000,000.0	$ 25,000,000.0
Period to repurchase common stock	24 months	24 months
Number of shares repurchased (shares)		500,000
Value of shares repurchased		$ 7,800,000
Affiliated Entity [Member]
Equity, Class of Treasury Stock [Line Items]
Write-off of investment		2,000,000
AngioVac Product [Member]
Equity, Class of Treasury Stock [Line Items]
Gain from reduction in fair value of liability		13,400,000
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment [Member] \| Discontinued Investment in TiLo Product [Member]
Equity, Class of Treasury Stock [Line Items]
Gain from reduction in fair value of liability		3,100,000
In Process Research and Development [Member] \| Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment [Member] \| Discontinued Investment in TiLo Product [Member]
Equity, Class of Treasury Stock [Line Items]
Write-off of In-process research and development		$ 3,600,000

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 19,057	$ 21,669
Work in process	11,947	10,700
Finished goods	26,677	23,001
Inventories	$ 57,681	$ 55,370

Other Assets (Details) - USD ($) $ in Millions		3 Months Ended
Other Assets (Details) - USD ($) $ in Millions	Dec. 07, 2015	Feb. 28, 2017
Related Party Transaction [Line Items]
Payments to Acquire Equity Method Investments	$ 2.0
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Write-off of investment		$ 2.0

Goodwill and Intangible Assets - Additional Information (Detail)		3 Months Ended		9 Months Ended
	Dec. 31, 2016 USD ($)	Feb. 28, 2017 USD ($)	Feb. 29, 2016 USD ($)	Feb. 28, 2017 USD ($) Segment	Feb. 29, 2016 USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of operating segments (segment) \| Segment				1
Number of reportable segments (segment) \| Segment				1
Amortization of intangibles		$ 4,360,000	$ 4,458,000	$ 12,886,000	$ 13,356,000
Goodwill impairment	$ 0
Goodwill adjustments				$ 0
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				18 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				1 year
Weighted Average [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				12 years 10 months 24 days

Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, excluding goodwill	$ 272,283	$ 278,927
Accumulated amortization	(122,205)	(112,350)
Net carrying value, finite intangible items	150,078
Net carrying value, excluding goodwill	150,078	166,577
Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived intangible items		3,600
Net carrying value, indefinite lived intangible items		3,600
Product Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	148,374	148,387
Accumulated amortization	(58,345)	(51,313)
Net carrying value, finite intangible items	90,029	97,074
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	88,322	88,389
Accumulated amortization	(50,131)	(47,133)
Net carrying value, finite intangible items	38,191	41,256
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	28,400	28,470
Accumulated amortization	(8,357)	(6,242)
Net carrying value, finite intangible items	20,043	22,228
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	5,037	7,931
Accumulated amortization	(4,289)	(6,716)
Net carrying value, finite intangible items	748	1,215
Distributor Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	2,150	2,150
Accumulated amortization	(1,083)	(946)
Net carrying value, finite intangible items	$ 1,067	$ 1,204

Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) $ in Thousands	Feb. 28, 2017 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 4,398
2018	16,849
2019	16,138
2020	14,556
2021	13,604
2022 and thereafter	84,533
Net carrying value, finite intangible items	$ 150,078

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$ 9,807	$ 9,414
Royalties	2,473	2,489
Accrued severance	1,606	1,524
Sales and franchise taxes	832	565
Outside services	1,085	2,063
Other	4,950	5,887
Total	$ 20,753	$ 21,942

Long Term Debt - Debt Outstanding (Details) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
Debt Instrument [Line Items]
Long term debt, gross	$ 98,750
Unamortized debt issuance costs	(1,231)
Long term debt, net	97,519
Current portion of long term debt	(5,000)	$ (16,250)
Long term debt, net of current maturities	92,519
Term Loan \| Credit Facility
Debt Instrument [Line Items]
Remainder of 2017	1,250
2018	5,000
2019	5,000
2020	7,500
2021	11,250
2022 and thereafter	68,750
Long term debt, gross	98,750
Revolving Credit Facility \| Credit Facility
Debt Instrument [Line Items]
Long term debt, gross	$ 0

Long Term Debt - Additional Information (Detail) - USD ($)		9 Months Ended
	Nov. 07, 2016	Feb. 28, 2017	Feb. 29, 2016
Debt Instrument [Line Items]
Proceeds from issuance of and borrowings on long-term debt		$ 116,471,000	$ 0
Repayments of former credit agreement		$ 139,131,000	$ 11,250,000
Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Debt maturity	5 years
Stated interest rate		2.29%
Percentage of increase in interest	2.00%
Maximum leverage ratio of indebtedness to adjusted EBITDA	3.50
Maximum leverage ratio of indebtedness to adjusted EBITDA following material acquisitions	3.75
Fixed charge coverage ratio of adjusted EBITDA minus capital expenditures to interested expense paid or payable plus scheduled principal payments	1.25
Credit Facility \| Minimum [Member] \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.20%
Credit Facility \| Maximum [Member] \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.35%
Credit Facility \| Base Rate [Member] \| Minimum [Member] \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Stated interest rate	0.50%
Credit Facility \| Base Rate [Member] \| Maximum [Member] \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Stated interest rate	1.25%
Credit Facility \| Eurodollar [Member] \| Minimum [Member] \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Stated interest rate	1.50%
Credit Facility \| Eurodollar [Member] \| Maximum [Member] \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Stated interest rate	2.25%
Term Loan \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	$ 100,000,000	$ 100,000,000
Proceeds from issuance of and borrowings on long-term debt	100,000,000
Revolving Credit Facility \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	150,000,000	150,000,000
Proceeds from issuance of and borrowings on long-term debt	16,500,000
Letter of Credit [Member] \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	20,000,000	20,000,000
Bridge Loan [Member] \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Line of credit	5,000,000	$ 5,000,000
Former Credit Agreement [Member] \| Credit Facility \| JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]
Debt Instrument [Line Items]
Repayments of former credit agreement	$ 116,500,000

Share-Based Compensation (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount of shares issuable through two stock-based compensation plans	9.5		9.5
Charges against income for share-based payment arrangements	$ 1.7	$ 1.7	$ 5.1	$ 4.5
Unrecognized compensation expenses related to share-based payment arrangements	$ 14.4		$ 14.4
Recognition period			4 years
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period				3 years

Equity (Details) - USD ($)		1 Months Ended	3 Months Ended	9 Months Ended
Equity (Details) - USD ($)	Nov. 06, 2016	Feb. 28, 2017	Feb. 28, 2017	Feb. 28, 2017	May 31, 2016
Equity, Class of Treasury Stock [Line Items]
Value of shares repurchased				$ 7,840,000
Treasury stock retirement				642,305
Common stock, par value		$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Common stock authorized for repurchase	$ 25,000,000.0	$ 25,000,000.0	$ 25,000,000.0	$ 25,000,000.0
Period to repurchase common stock	24 months		24 months
Number of shares repurchased (shares)			500,000
Value of shares repurchased			$ 7,800,000
Remaining common stock available for repurchase		17,200,000	$ 17,200,000	17,200,000
Additional Paid-in Capital [Member]
Equity, Class of Treasury Stock [Line Items]
Treasury stock retirement, carrying value		$ 9,900,000		$ (9,942,000)
Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Treasury stock retirement		642,305		(642,305)
Treasury stock retirement, carrying value		$ 9,900,000		$ (2,000)

Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016
Earnings Per Share [Abstract]
Basic (shares)	36,625	36,146	36,557	36,083
Effect of dilutive securities (shares)	501	244	511	0
Diluted (shares)	37,126	36,390	37,068	36,083
Securities excluded as their inclusion would be anti-dilutive (shares)	1,040	3,394	973	3,038

Segment and Geographic Information - Additional Information (Detail)	9 Months Ended
	Feb. 28, 2017 Segment
Segment Reporting [Abstract]
Number of operating segments (segment)	1

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016
Segment Reporting Information [Line Items]
Net sales	$ 85,602	$ 87,434	$ 262,729	$ 260,471
Peripheral Vascular [Member]
Segment Reporting Information [Line Items]
Net sales	48,496	49,779	152,800	147,940
Vascular Access [Member]
Segment Reporting Information [Line Items]
Net sales	23,680	24,911	72,238	74,576
Oncology/Surgery [Member]
Segment Reporting Information [Line Items]
Net sales	12,993	12,054	35,837	35,859
Supply Agreement [Member]
Segment Reporting Information [Line Items]
Net sales	$ 433	$ 690	$ 1,854	$ 2,096

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016
Net Sales
Net sales	$ 85,602	$ 87,434	$ 262,729	$ 260,471
Supply Agreement [Member]
Net Sales
Net sales	433	690	1,854	2,096
Reportable Geographical Components [Member] \| United States [Member]
Net Sales
Net sales	67,366	69,501	209,901	208,523
Reportable Geographical Components [Member] \| International [Member]
Net Sales
Net sales	17,803	17,243	50,974	49,852
Reportable Geographical Components [Member] \| Supply Agreement [Member]
Net Sales
Net sales	$ 433	$ 690	$ 1,854	$ 2,096

Fair Value - Additional Information (Detail) $ in Millions	3 Months Ended
Fair Value - Additional Information (Detail) $ in Millions	Feb. 28, 2017 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Potential amount of undiscounted future contingent consideration	$ 13.0
AngioVac Product [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain from reduction in fair value of liability	13.4
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment [Member] \| Discontinued Investment in TiLo Product [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain from reduction in fair value of liability	3.1
In Process Research and Development [Member] \| Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment [Member] \| Discontinued Investment in TiLo Product [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Write-off of In-process research and development	$ 3.6

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
Recurring [Member]
Financial Assets
Marketable securities	$ 1,203	$ 1,653
Total Financial Assets	1,203	1,653
Financial Liabilities
Total Financial Liabilities	12,635	38,275
Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,203	1,653
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	12,635
Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities		38,275
Level 1 [Member] \| Recurring [Member]
Financial Assets
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 1 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 2 [Member] \| Recurring [Member]
Financial Assets
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	0	0
Level 2 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 2 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 3 [Member] \| Recurring [Member]
Financial Assets
Marketable securities	1,203	1,653
Total Financial Assets	1,203	1,653
Financial Liabilities
Total Financial Liabilities	12,635	38,275
Level 3 [Member] \| Recurring [Member] \| U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,203	1,653
Level 3 [Member] \| Contingent Consideration Earn Out Liability [Member] \| Recurring [Member]
Financial Liabilities
Total Financial Liabilities	$ 12,635	$ 38,275

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Feb. 28, 2017	Feb. 28, 2017
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Financial assets, begining balance	$ 1,203	$ 1,653
Currency gain (loss) from remeasurement, assets		0
Proceeds from sale or maturity of marketable securities, assets		(450)
Contingent consideration - Clinical Devices, assets		0
Financial assets, ending balance	1,203	1,203
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Financial liabilities, begining balance	12,513	38,275
Change in Fair Value of Contingent Consideration	122	(15,386)
Currency gain (loss) from remeasurement, liabilities		(154)
Proceeds from sale or maturity of marketable securities, liabilities		0
Financial liabilities, ending balance	$ 12,635	12,635
Clinical Devices B.V [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration - Clinical Devices, liabilities		$ (10,100)

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	9 Months Ended
	Feb. 28, 2017	Nov. 30, 2016	May 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	$ 12,635	$ 12,513	$ 38,275
Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	12,635
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	12,635		38,275
Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities			38,275
Level 3 [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	12,635		38,275
Level 3 [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	12,635		$ 38,275
Level 3 [Member] \| Revenue Based Payments [Member] \| Recurring [Member] \| Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value	$ 12,635
Discount rate	4.00%
Probability of payment	100.00%

Marketable Securities - Additional Information (Detail) $ in Millions	Feb. 28, 2017 USD ($) Investment	May 31, 2016 USD ($)
Marketable Securities [Abstract]
Investments in auction rate securities that failed auctions \| $	$ 1.2	$ 1.7
Number of investments (investment) \| Investment	1

Marketable Securities - Marketable Securities (Detail) - USD ($) $ in Thousands	Feb. 28, 2017	May 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 1,350	$ 1,800
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(147)	(147)
Fair Value	1,203	1,653
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,350	1,800
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(147)	(147)
Fair Value	$ 1,203	$ 1,653

Commitments and Continfencies - Additional Information (Detail) $ in Millions										9 Months Ended
	Mar. 29, 2016 claim	Mar. 24, 2016 claim	Mar. 11, 2016 claim	Jun. 01, 2015 motion	Mar. 10, 2015 patent	Mar. 18, 2014 USD ($)	Nov. 08, 2012 USD ($)	Jan. 11, 2012 reexamination_appeal claim	Jan. 02, 2008 Lawsuit	Feb. 28, 2017 Petition reexamination_appeal
Loss Contingencies [Line Items]
Litigation settlement amount \| $						$ 74.9
Biolitec [Member]
Loss Contingencies [Line Items]
Number of lawsuits against biolitec previously settled for which seeking defense and indemnification \| Lawsuit									2
Partial judgment granted \| $							$ 23.2
C.R. Bard, Inc. [Member]
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents \| Petition										3
The Utah Action [Member]
Loss Contingencies [Line Items]
Patent claims								41,000
Number of claims dismissed	20	8	6					40
Number of reexaminations \| reexamination_appeal								3
Number of pending claims		10	10
Number of claims reversed		2	4
The Utah Action [Member] \| Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of reexaminations \| reexamination_appeal										2
The Delaware Action [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				2	3
C.R. Bard, Inc. [Member] \| The Utah Action [Member] \| Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of reexaminations \| reexamination_appeal										3

Acquisition, Restructuring and Other Items, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2017	Feb. 29, 2016
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 1,750	$ 3,042	$ 12,028	$ 9,098
Legal Costs [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	1,528	1,468	5,162	5,402
Intangible Impairment [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	0	0	5,604	384
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	217	0	217	0
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 5	$ 1,574	$ 1,045	$ 3,312

Acquisition, Restructuring and Other Items, Net - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2017	Feb. 28, 2017	May 31, 2016
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 200,000	$ 200,000	$ 0
Cash payments associated with restructuring initiatives	0
Restructuring liability	$ 200,000	$ 200,000

Acquisition, Restructuring and Other Items, Net - Expected Restructuring Costs (Details) $ in Thousands	Feb. 01, 2017 USD ($)
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	$ 6,250
Minimum [Member] \| One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,750
Minimum [Member] \| Equipment Transfer [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	2,000
Minimum [Member] \| Regulatory Filings [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	800
Minimum [Member] \| Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	800
Minimum [Member] \| Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	800
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	7,750
Maximum [Member] \| One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	2,250
Maximum [Member] \| Equipment Transfer [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	2,500
Maximum [Member] \| Regulatory Filings [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,000
Maximum [Member] \| Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,000
Maximum [Member] \| Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Estimated costs	$ 1,000

Acquisition, Restructuring and Other Items, Net - Costs Incurred (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Feb. 28, 2017	Feb. 28, 2017
One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 202	$ 202
Equipment Transfer [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred	0	0
Regulatory Filings [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred	0	0
Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred	0	0
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 15	$ 15

Recently Issued Accounting Pronouncements (Details) - Accounting Standards Update 2015-03 [Member] $ in Millions	May 31, 2016 USD ($)
Other Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred financing fees	$ (0.9)
Long-term Debt [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred financing fees	$ 0.9

Income Taxes - Additional Information (Detail)	3 Months Ended
Income Taxes - Additional Information (Detail)	Feb. 28, 2017	Feb. 29, 2016
Income Tax Disclosure [Abstract]
Estimated federal statutory income tax rate	42.90%	46.00%